Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2010 Oct 8;26(5):381–387. doi: 10.1007/s12264-010-0410-9

Progressive changes of orexin system in a rat model of 6-hydroxydopamineinduced Parkinson’s disease

6- 羟多巴诱致帕金森病大鼠模型中orexin 系统的进行性变化

Cui Long-Biao 1,2, Li Bo-Wei 1,2, Jin Xiao-Hang 1, Zhao Lin 3, Shi Juan 1,✉
PMCID: PMC5552601  PMID: 20882064

Abstract

Objective

Sleep disturbance, which is characterized by excessive daytime sleepiness and sleep attacks, is frequently observed in patients with Parkinson’s disease (PD). Loss of orexin neurons in hypothalamus and the resultant decreased level of orexin in cerebrospinal fluid (CSF) found in narcolepsy patients may also play an essential role in the pathogenesis of sleep disturbance. The present study aimed to investigate the possible changes in the orexin system during PD progression.

Methods

After the establishment of a rat PD model by injecting 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle, the numbers of orexin-A- and tyrosine hydroxylase (TH)-positive neurons, and the levels of orexin-A fibers and orexin-A in CSF were examined by immunohistochemistry and ELISA assay, respectively.

Results

Compared to the TH-containing neurons that exhibited fast degeneration in response to 6-OHDA, orexin-A-containing neurons were less sensitive to 6-OHDA. The number of orexin-A-positive neurons began to decrease at day 21 after operation, and at day 49, it decreased by 30% of the initial level. The orexin-A level in CSF of PD rats did not show any obvious fluctuations compared to the control, and there was no obvious reduction in the density of orexin-A-positive fibers in brain areas such as tuberomammillary nucleus.

Conclusion

These results reveal for the first time the dynamic changes of orexin system during the progression of PD. This may provide valuable information for drug development to reverse the loss of orexin neurons and sleep disturbance in PD patients.

Keywords: orexin, Parkinson’s disease, sleep disturbance, degeneration

Footnotes

An erratum to this article is available at http://dx.doi.org/10.1007/s12264-016-0043-8.

References

  • [1].Fronczek R., Baumann C.R., Lammers G.J., Bassetti C.L., Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev. 2009;13:9–22. doi: 10.1016/j.smrv.2008.05.002. [DOI] [PubMed] [Google Scholar]
  • [2].Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365–376. doi: 10.1016/S0092-8674(00)81965-0. [DOI] [PubMed] [Google Scholar]
  • [3].Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437–451. doi: 10.1016/S0092-8674(00)81973-X. [DOI] [PubMed] [Google Scholar]
  • [4].Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40. doi: 10.1016/S0140-6736(99)05582-8. [DOI] [PubMed] [Google Scholar]
  • [5].Hobson D.E., Lang A.E., Martin W.R., Razmy A., Rivest J., Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287:455–463. doi: 10.1001/jama.287.4.455. [DOI] [PubMed] [Google Scholar]
  • [6].Arnulf I., Bonnet A.M., Damier P., Bejjani B.P., Seilhean D., Derenne J.P., et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55:281–288. doi: 10.1212/wnl.55.2.281. [DOI] [PubMed] [Google Scholar]
  • [7].Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Créange A., Remy P., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology. 2003;61:540–543. doi: 10.1212/01.wnl.0000078194.53210.48. [DOI] [PubMed] [Google Scholar]
  • [8].Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., et al. Hypocretin (orexin) loss in Parkinson’s disease. Brain. 2007;130:1577–1585. doi: 10.1093/brain/awm090. [DOI] [PubMed] [Google Scholar]
  • [9].Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130:1586–1595. doi: 10.1093/brain/awm097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Asai H., Hirano M., Furiya Y., Udaka F., Morikawa M., Kanbayashi T., et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin Neurol Neurosurg. 2009;111:341–344. doi: 10.1016/j.clineuro.2008.11.007. [DOI] [PubMed] [Google Scholar]
  • [11].Poceta J.S., Parsons L., Engelland S., Kripke D.F. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson’s disease. Sleep Med. 2009;10:129–133. doi: 10.1016/j.sleep.2007.11.002. [DOI] [PubMed] [Google Scholar]
  • [12].Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell linederived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats. Proc Natl Acad Sci U S A. 1997;94:14083–14088. doi: 10.1073/pnas.94.25.14083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Chen C.T., Dun S.L., Kwok E.H., Dun N.J., Chang J.K. Orexin A-like immunoreactivity in the rat brain. Neurosci Lett. 1999;260:161–164. doi: 10.1016/S0304-3940(98)00977-X. [DOI] [PubMed] [Google Scholar]
  • [14].Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. J Neurochem. 2009;110:966–975. doi: 10.1111/j.1471-4159.2009.06189.x. [DOI] [PubMed] [Google Scholar]
  • [15].Gerashchenko D., Murillo-Rodriguez E., Lin L., Xu M., Hallett L., Nishino S., et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol. 2003;184:1010–1016. doi: 10.1016/S0014-4886(03)00388-1. [DOI] [PubMed] [Google Scholar]
  • [16].Jeon B.S., Jackson-Lewis V., Burke R.E. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration. 1995;4:131–137. doi: 10.1006/neur.1995.0016. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES